RecruitingNCT06417502
Observational Study of Pediatric Rheumatic and Immunologic Diseases in China: The CAPRID Registry
Sponsor
Peking Union Medical College Hospital
Enrollment
20,000 participants
Start Date
Apr 29, 2022
Study Type
OBSERVATIONAL
Conditions
Summary
An observational, multi-center, longitudinal registry study for Chinese pediatric patients with rheumatic and immunologic diseases.
Eligibility
Max Age: 18 Years
Inclusion Criteria3
- Age \<= 18 years old
- Diagnosed with rheumatic and immunologic diseases (including diffuse connective tissue diseases, arthritis, vasculitis, inborn errors of immunity)
- Diagnosed and Treated in China
Exclusion Criteria1
- Disagreement of involving in this study by the patient or his/her family.
Locations(9)
View Full Details on ClinicalTrials.gov
For the most up-to-date information, visit the official listing.
NCT06417502
Related Trials
Clinical Study on Targeted CD19 or CD19-BCMA CAR-T Therapy for Autoimmune Diseases
NCT065486071 location
Study to Evaluate the Safety and Feasibility of Diamyd® in Individuals at Risk for Type 1 Diabetes
NCT056839901 location
Ovarian Tissue Cryopreservation for Fertility Preservation
NCT058751551 location
A Study to Investigate Safety and Effectiveness of Porcine Pancreatic Cells (OPF-310) in Patients With Type 1 Diabetes Mellitus
NCT065754261 location
Exploratory Clinical Study on the Safety and Efficacy of Anti- CD19/BCMA U CAR-T Cell Injection for the Treatment of Relapsed/Refractory Autoimmune Diseases
NCT072460961 location